John O. Mascarenhas, MD, discusses the current treatment options for patients with myelofibrosis.
John O. Mascarenhas, MD
Advertisement
Articles by John O. Mascarenhas, MD
John O. Mascarenhas, MD, discusses pacritinib for patients with myelofibrosis and thrombocytopenia.
John O. Mascarenhas, MD, associate professor of medicine, Icahn School of Medicine at Mount Sinai Hospital, discusses the optimal use of ruxolitinib (Jakafi) and the improved understanding of JAK2 inhibition of polycythemia vera.
Advertisement
Latest Updated Articles
Improved Understanding of JAK2 Inhibition in Polycythemia VeraPublished: November 9th 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
